Technology areas: Biotechnology & Pharmaceuticals • Transportation, E-Commerce & Mechanical Systems
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Omniseq Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners and 2 distinct art units, showing that current prosecution is divided across separate examination assignments. This distribution calls for coordinated portfolio oversight, but the response to each action should remain tied to its own examiner and art-unit context.
SALMON, KATHERINE D is the busiest examiner, with 1 pending matter. No examiner accounts for all of the identified pending activity, so counsel should not assume that one response strategy will govern the portfolio. Reviewing the actions together may reveal common biotechnology themes, while separate prosecution records remain necessary.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SALMON, KATHERINE D | 1 | 42.7% | +38.2% |
| WHALEY, PABLO S | 1 | 25.0% | +21.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18055292 | Methods and Systems for Analyzing and Utilizing Cancer Testis Antigen Burden | SALMON, KATHERINE D | 55d |
| 17452873 | METHODS AND SYSTEMS FOR CHARACTERIZING TUMOR RESPONSE TO IMMUNOTHERAPY USING AN IMMUNOGENIC PROFILE | WHALEY, PABLO S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18055292 | Methods and Systems for Analyzing and Utilizing Cancer Testis Antigen Burden | SALMON, KATHERINE D | 55d |
| 17452873 | METHODS AND SYSTEMS FOR CHARACTERIZING TUMOR RESPONSE TO IMMUNOTHERAPY USING AN IMMUNOGENIC PROFILE | WHALEY, PABLO S | — |
| Art Unit | Apps |
|---|---|
| 1682 | 1 |
| 3619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18055292 | Methods and Systems for Analyzing and Utilizing Cancer Testis Antigen Burden | SALMON, KATHERINE D | 1682 | §101§103§112Other | Final Rejection | 55d | Pending | Nov 14, 2022 |
| 17452873 | METHODS AND SYSTEMS FOR CHARACTERIZING TUMOR RESPONSE TO IMMUNOTHERAPY USING AN IMMUNOGENIC PROFILE | WHALEY, PABLO S | 3619 | §101§103§112 | Final Rejection | — | Pending | Oct 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOmniseq Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Katherine D Salmon has the most, with 1 of Omniseq Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.